Precision BioSciences Q4 GAAP EPS $(4.06) May Not Be Comparable To $(2.05) Estimate, Sales $7.04M Miss $12.48M Estimate
Portfolio Pulse from Benzinga Newsdesk
Precision BioSciences (NASDAQ:DTIL) reported a Q4 GAAP EPS loss of $(4.06), missing the consensus estimate of $(2.05) by 98.05%. Year-over-year, this represents a 47.27% decrease in losses from $(7.70) per share. However, Q4 sales of $7.04M fell short of the $12.48M estimate by 43.61%, marking a 33.59% decrease from the previous year's $10.60M.
March 27, 2024 | 10:48 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Precision BioSciences reported a significant miss in both EPS and sales for Q4, with a larger-than-expected loss and a notable decrease in sales compared to analyst estimates.
The significant miss in both EPS and sales for Precision BioSciences in Q4 is likely to negatively impact investor sentiment and stock price in the short term. The EPS loss was nearly double the estimate, and sales fell significantly short of expectations, indicating potential operational and market challenges.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100